Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8<sup>+</sup> T cell exhaustion.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32908154.
- Also identified by DOI 10.1038/s41467-020-18298-8 and PMC identifier 7481212.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Tumor extracellular matrix has been associated with drug resistance and immune suppression. Here, proteomic and RNA profiling reveal increased collagen levels in lung tumors resistant to PD-1/PD-L1 blockade. Additionally, elevated collagen correlates with decreased total CD8<sup>+</sup> T cells and increased exhausted CD8<sup>+</sup> T cell subpopulations in murine and human lung tumors. Collagen-induced T cell exhaustion occurs through the receptor LAIR1, which is upregulated following CD18 interaction with collagen, and induces T cell exhaustion through SHP-1. Reduction in tumor collagen deposition through LOXL2 suppression increases T cell infiltration, diminishes exhausted T cells, and abrogates resistance to anti-PD-L1. Abrogating LAIR1 immunosuppression through LAIR2 overexpression or SHP-1 inhibition sensitizes resistant lung tumors to anti-PD-1. Clinically, increased collagen, LAIR1, and TIM-3 expression in melanoma patients treated with PD-1 blockade predict poorer survival and response. Our study identifies collagen and LAIR1 as potential markers for immunotherapy resistance and validates multiple promising therapeutic combinations.
Medical subject headings
- Adenocarcinoma of Lung
- Antineoplastic Agents, Immunological
- CD8-Positive T-Lymphocytes
- Collagen
- Drug Resistance, Neoplasm
- Lung Neoplasms
- Receptors, Immunologic